Hospital
Augusta Health Care, INC
Augusta Health Care, INC was paid $63.57M by Medicaid between Jan 2018 and Dec 2024, across 426 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 18% of everything it billed.
33Billing provider infoAUGUSTA HEALTH CARE, INC
FISHERSVILLE, VA 22939
FISHERSVILLE, VA 22939
33aNPI1053301127assigned 10/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$63.57M
24GClaims1,638,072
24DCodes billed426
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#11 of 80
Median peer was paid$14.69M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 166,306 | $3.69M | |
| 2019 | 247,174 | $7.00M | |
| 2020 | 227,095 | $8.32M | |
| 2021 | 244,526 | $9.40M | |
| 2022 | 253,276 | $10.98M | |
| 2023 | 276,607 | $13.12M | |
| 2024incomplete | 223,088 | $11.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18% | 100,184 | 80,772 | $11.48M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 46,380 | 40,411 | $7.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 40,141 | 33,736 | $6.54M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.2% | 19,260 | 15,197 | $5.23M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 21,822 | 18,742 | $3.90M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 13,450 | 12,095 | $2.01M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 8,812 | 7,898 | $1.80M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 27,618 | 25,876 | $1.52M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 8,277 | 7,345 | $1.40M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 27,141 | 8,253 | $1.27M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 2,320 | 2,117 | $1.13M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 6,874 | 5,900 | $1.12M |
414 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 1,400 | $810K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 4,424 | $784K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 2,534 | $773K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 7,565 | $728K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 3,451 | $674K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 4,245 | $603K |
| G0378 | Hospital observation service, per hour | <1% | 13,529 | $592K |
| 59025 | Fetal non-stress test | <1% | 3,785 | $576K |
| 97163 | <1% | 4,589 | $522K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,904 | $458K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,150 | $442K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,109 | $431K |
| 80053 | Comprehensive metabolic panel | <1% | 80,453 | $420K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 645 | $380K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 557 | $275K |
| 93971 | <1% | 2,991 | $259K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,280 | $251K |
| 12001 | <1% | 1,088 | $241K | |
| 62323 | <1% | 488 | $229K | |
| 76642 | <1% | 1,951 | $225K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,394 | $223K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 164 | $206K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,894 | $204K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,904 | $193K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,317 | $190K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,266 | $189K |
| 76775 | <1% | 2,320 | $189K | |
| 95886 | <1% | 951 | $188K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,890 | $183K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 232 | $178K |
| 96367 | <1% | 2,032 | $169K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,891 | $159K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,585 | $159K |
| 74018 | <1% | 4,584 | $152K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,824 | $147K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 523 | $144K |
| 95806 | <1% | 239 | $143K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 70,059 | $136K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,308 | $134K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,396 | $131K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,372 | $125K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 68 | $113K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,706 | $112K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,265 | $108K |
| 10060 | <1% | 727 | $105K | |
| 58661 | <1% | 34 | $102K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,308 | $96K |
| 80061 | Lipid panel | <1% | 16,083 | $89K |
| 93017 | <1% | 1,041 | $85K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,799 | $84K |
| 76536 | <1% | 698 | $82K | |
| 72141 | <1% | 348 | $79K | |
| 85027 | <1% | 26,002 | $77K | |
| 87081 | <1% | 17,072 | $77K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,212 | $77K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 96 | $76K |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,813 | $75K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,295 | $75K |
| 71250 | <1% | 1,089 | $75K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,806 | $72K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,632 | $71K |
| 87430 | <1% | 11,120 | $71K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,104 | $68K |
| 64483 | <1% | 107 | $67K | |
| 20610 | <1% | 326 | $66K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,524 | $64K |
| 73610 | <1% | 3,911 | $62K | |
| 20552 | <1% | 337 | $62K | |
| 83880 | <1% | 5,380 | $62K | |
| 29125 | <1% | 387 | $60K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 302 | $59K |
| 93296 | <1% | 2,720 | $58K | |
| 73630 | <1% | 3,973 | $58K | |
| 93970 | <1% | 469 | $57K | |
| E1390 | Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate | <1% | 1,913 | $53K |
| 71271 | <1% | 470 | $51K | |
| 90715 | <1% | 2,292 | $48K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,233 | $47K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,840 | $47K |
| 64615 | <1% | 146 | $46K | |
| 73564 | <1% | 3,513 | $46K | |
| 86803 | <1% | 5,256 | $45K | |
| 97161 | <1% | 690 | $45K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,524 | $44K |
| 87400 | <1% | 7,092 | $44K | |
| 97113 | <1% | 986 | $44K | |
| 84439 | <1% | 7,565 | $42K | |
| 73130 | <1% | 2,723 | $42K | |
| 82728 | <1% | 5,229 | $38K | |
| 73030 | <1% | 2,928 | $38K | |
| 81025 | <1% | 18,247 | $37K | |
| 80306 | <1% | 8,182 | $36K | |
| 84484 | <1% | 21,615 | $36K | |
| 73110 | <1% | 2,371 | $35K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,071 | $34K |
| 72100 | <1% | 1,197 | $34K | |
| 12002 | <1% | 165 | $33K | |
| 70496 | <1% | 127 | $32K | |
| 97116 | <1% | 1,752 | $32K | |
| 82607 | <1% | 4,642 | $32K | |
| 72110 | <1% | 2,129 | $32K | |
| 29581 | <1% | 356 | $31K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,002 | $30K |
| 74420 | <1% | 195 | $30K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 139 | $30K |
| 73140 | <1% | 1,415 | $30K | |
| 87077 | <1% | 9,372 | $28K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,220 | $28K |
| 86780 | <1% | 2,999 | $28K | |
| 81001 | <1% | 30,696 | $26K | |
| 83690 | <1% | 20,939 | $26K | |
| 87186 | <1% | 9,124 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,462 | $25K |
| 86140 | <1% | 7,257 | $25K | |
| 20553 | <1% | 176 | $25K | |
| 84466 | <1% | 4,912 | $24K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 996 | $24K |
| 82248 | <1% | 8,106 | $23K | |
| 77080 | <1% | 456 | $22K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 25,081 | $22K |
| 73502 | <1% | 2,011 | $21K | |
| 84702 | <1% | 3,977 | $21K | |
| 70491 | <1% | 157 | $20K | |
| 72040 | <1% | 549 | $20K | |
| 12011 | <1% | 85 | $18K | |
| 85379 | <1% | 4,934 | $18K | |
| 97165 | <1% | 321 | $18K | |
| 87340 | <1% | 3,287 | $18K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 202 | $18K |
| 83735 | <1% | 10,449 | $17K | |
| 83540 | <1% | 5,523 | $17K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 173 | $17K |
| 85652 | <1% | 6,643 | $17K | |
| 74019 | <1% | 874 | $17K | |
| 94060 | <1% | 327 | $16K | |
| 97162 | <1% | 190 | $16K | |
| 94729 | <1% | 592 | $16K | |
| 87040 | <1% | 3,250 | $16K | |
| 80050 | General health panel | <1% | 2,116 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,446 | $16K |
| 82746 | <1% | 2,875 | $16K | |
| 70486 | <1% | 382 | $15K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,836 | $15K |
| 80076 | <1% | 4,176 | $15K | |
| 74178 | <1% | 42 | $15K | |
| 87428 | <1% | 612 | $15K | |
| 87147 | <1% | 6,123 | $14K | |
| 80055 | <1% | 571 | $14K | |
| 72114 | <1% | 436 | $14K | |
| 74183 | <1% | 42 | $14K | |
| 86704 | <1% | 1,980 | $13K | |
| 83970 | <1% | 827 | $13K | |
| 64493 | <1% | 12 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,591 | $12K |
| 86038 | <1% | 1,875 | $12K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 87 | $12K |
| 36591 | <1% | 2,516 | $12K | |
| 82043 | <1% | 4,660 | $12K | |
| 87522 | Neg quan hep c or qual rna | <1% | 416 | $11K |
| 86706 | <1% | 2,443 | $11K | |
| 84480 | <1% | 1,386 | $11K | |
| 87088 | <1% | 4,043 | $11K | |
| 80143 | <1% | 1,991 | $11K | |
| 81003 | <1% | 12,378 | $10K | |
| 76870 | <1% | 116 | $10K | |
| 85610 | <1% | 9,098 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 76 | $10K |
| C1769 | Guide wire | <1% | 1,815 | $10K |
| 87493 | <1% | 745 | $10K | |
| 73080 | <1% | 1,061 | $10K | |
| 71101 | <1% | 852 | $10K | |
| 93298 | <1% | 251 | $10K | |
| 86403 | <1% | 2,047 | $9K | |
| 29515 | <1% | 87 | $9K | |
| 84403 | <1% | 633 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,850 | $9K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 26 | $9K |
| 82784 | <1% | 1,657 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 780 | $8K |
| 87070 | <1% | 2,680 | $8K | |
| 69209 | <1% | 80 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,379 | $8K |
| 80329 | <1% | 1,055 | $8K | |
| 86364 | <1% | 604 | $8K | |
| 86756 | <1% | 935 | $8K | |
| 73590 | <1% | 641 | $7K | |
| 86787 | <1% | 1,263 | $7K | |
| 80179 | <1% | 1,934 | $7K | |
| 86708 | <1% | 1,346 | $7K | |
| 83605 | <1% | 4,535 | $7K | |
| 87210 | <1% | 3,035 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 437 | $7K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 37 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,969 | $7K |
| 94726 | <1% | 261 | $7K | |
| 95812 | <1% | 14 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,174 | $6K |
| 82077 | <1% | 3,060 | $6K | |
| 83001 | <1% | 559 | $6K | |
| 84703 | <1% | 2,605 | $6K | |
| 84146 | <1% | 506 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,206 | $6K |
| 86900 | <1% | 4,013 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 404 | $5K |
| 83516 | <1% | 774 | $5K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 2,862 | $5K |
| 86762 | <1% | 596 | $5K | |
| 85730 | <1% | 4,021 | $5K | |
| 80320 | <1% | 1,277 | $5K | |
| 73090 | <1% | 572 | $5K | |
| 80164 | <1% | 768 | $5K | |
| 77062 | <1% | 106 | $5K | |
| 96376 | <1% | 9,107 | $5K | |
| 86235 | <1% | 254 | $5K | |
| 82803 | <1% | 2,194 | $5K | |
| 86850 | <1% | 3,057 | $5K | |
| 73562 | <1% | 167 | $5K | |
| 82565 | <1% | 4,589 | $5K | |
| E0431 | Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing | <1% | 719 | $5K |
| 87205 | <1% | 2,672 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,753 | $5K |
| 64494 | <1% | 12 | $4K | |
| 97167 | <1% | 25 | $4K | |
| 82950 | <1% | 928 | $4K | |
| 86901 | <1% | 4,066 | $4K | |
| 82570 | <1% | 1,704 | $4K | |
| 93299 | <1% | 212 | $4K | |
| 86431 | <1% | 1,091 | $4K | |
| 95910 | <1% | 67 | $4K | |
| 84550 | <1% | 941 | $3K | |
| 86200 | <1% | 429 | $3K | |
| 84100 | <1% | 4,424 | $3K | |
| 36430 | <1% | 15 | $3K | |
| 87449 | <1% | 784 | $3K | |
| 77002 | <1% | 42 | $3K | |
| 86709 | <1% | 654 | $3K | |
| 80047 | <1% | 603 | $3K | |
| 93225 | <1% | 79 | $3K | |
| 70498 | <1% | 110 | $3K | |
| 82550 | <1% | 1,374 | $3K | |
| 86618 | <1% | 276 | $3K | |
| 87427 | <1% | 590 | $3K | |
| 85014 | <1% | 1,409 | $3K | |
| 77336 | <1% | 34 | $3K | |
| 87905 | <1% | 449 | $3K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 153 | $3K |
| 83002 | <1% | 285 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,686 | $3K |
| 83993 | <1% | 211 | $3K | |
| 97166 | <1% | 31 | $2K | |
| 84153 | <1% | 220 | $2K | |
| 83525 | <1% | 294 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 185 | $2K |
| 73120 | <1% | 99 | $2K | |
| 72052 | <1% | 78 | $2K | |
| 97542 | <1% | 153 | $2K | |
| 87045 | <1% | 590 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,302 | $2K |
| 80178 | <1% | 328 | $2K | |
| 90686 | <1% | 175 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,207 | $2K |
| 93226 | <1% | 79 | $2K | |
| 97803 | <1% | 89 | $2K | |
| 84450 | <1% | 519 | $2K | |
| 84460 | <1% | 533 | $2K | |
| 86480 | <1% | 87 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,105 | $1K |
| 86160 | <1% | 267 | $1K | |
| 76882 | <1% | 15 | $1K | |
| E0570 | Nebulizer, with compressor | <1% | 58 | $1K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,571 | $1K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,604 | $1K |
| 83615 | <1% | 925 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 16 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,645 | $1K |
| 99234 | <1% | 158 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,840 | $1K |
| 96368 | <1% | 76 | $1K | |
| 87808 | <1% | 350 | $1K | |
| 97802 | <1% | 66 | $1K | |
| 72070 | <1% | 42 | $1K | |
| 93356 | <1% | 741 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,716 | $1K |
| 86308 | <1% | 332 | $1K | |
| 84478 | <1% | 292 | $853.16 | |
| 85018 | <1% | 469 | $785.51 | |
| 93242 | <1% | 12 | $748.31 | |
| 72050 | <1% | 42 | $724.09 | |
| 87529 | <1% | 12 | $716.44 | |
| 82670 | <1% | 50 | $710.16 | |
| 93280 | <1% | 40 | $691.63 | |
| 77061 | <1% | 12 | $690.13 | |
| 81002 | <1% | 514 | $677.39 | |
| 91322 | <1% | 14 | $660.28 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,928 | $653.27 |
| 86037 | <1% | 86 | $648.62 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,741 | $599.50 |
| 82977 | <1% | 144 | $578.41 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 764 | $568.64 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 38 | $554.43 |
| 83721 | <1% | 69 | $553.64 | |
| 94762 | <1% | 15 | $532.59 | |
| 76376 | <1% | 941 | $516.41 | |
| 87480 | <1% | 40 | $498.99 | |
| 87660 | <1% | 40 | $494.37 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,928 | $487.77 |
| 76942 | <1% | 43 | $474.83 | |
| 84145 | <1% | 65 | $467.45 | |
| 87510 | <1% | 40 | $466.67 | |
| 86376 | <1% | 45 | $463.29 | |
| 82105 | <1% | 83 | $441.99 | |
| 72072 | <1% | 27 | $424.88 | |
| G0008 | Administration of influenza virus vaccine | <1% | 94 | $423.09 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,670 | $379.05 |
| 82150 | <1% | 89 | $339.91 | |
| 90656 | <1% | 18 | $338.26 | |
| 82951 | <1% | 25 | $331.32 | |
| 86677 | <1% | 25 | $319.84 | |
| 73523 | <1% | 12 | $318.20 | |
| 82010 | <1% | 868 | $318.04 | |
| 90480 | <1% | 13 | $268.98 | |
| 84520 | <1% | 320 | $267.76 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,787 | $219.60 |
| 86039 | <1% | 41 | $219.37 | |
| A7035 | Headgear used with positive airway pressure device | <1% | 13 | $218.04 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,256 | $214.33 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 640 | $212.08 |
| J2704 | Injection, propofol, 10 mg | <1% | 17,447 | $210.17 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,987 | $202.88 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,455 | $201.41 |
| A7038 | Filter, disposable, used with positive airway pressure device | <1% | 100 | $199.68 |
| 84481 | <1% | 18 | $199.10 | |
| 82365 | <1% | 62 | $198.19 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,486 | $196.13 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 166 | $191.59 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,417 | $190.74 |
| 73560 | <1% | 33 | $190.59 | |
| 84144 | <1% | 24 | $189.61 | |
| E0601 | Continuous positive airway pressure (cpap) device | <1% | 16 | $178.84 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,292 | $175.06 |
| 86920 | <1% | 15 | $172.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 708 | $161.68 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 355 | $158.57 |
| A0425 | Ground mileage, per statute mile | <1% | 351 | $144.73 |
| 72170 | <1% | 31 | $141.14 | |
| 87075 | <1% | 71 | $136.68 | |
| 74022 | <1% | 116 | $132.95 | |
| A7037 | Tubing used with positive airway pressure device | <1% | 16 | $131.67 |
| 84165 | <1% | 29 | $120.30 | |
| 73660 | <1% | 15 | $118.40 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,963 | $108.63 |
| 82040 | <1% | 25 | $106.43 | |
| 82952 | <1% | 25 | $104.24 | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,300 | $96.24 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,928 | $95.74 |
| 82247 | <1% | 17 | $92.90 | |
| 73552 | <1% | 17 | $86.70 | |
| 86008 | <1% | 16 | $84.18 | |
| 0352U | <1% | 67 | $83.35 | |
| 86674 | <1% | 13 | $72.28 | |
| 82270 | <1% | 26 | $53.84 | |
| 89051 | <1% | 37 | $53.55 | |
| 86225 | <1% | 14 | $51.33 | |
| 82465 | <1% | 16 | $46.89 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 55 | $43.62 |
| 80305 | <1% | 13 | $37.80 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 373 | $36.80 |
| 73060 | <1% | 15 | $31.96 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,104 | $28.50 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 449 | $25.90 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 295 | $22.17 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 440 | $15.03 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 187 | $13.71 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 210 | $11.30 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 132 | $6.00 |
| 99152 | <1% | 33 | $5.38 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 115 | $5.37 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 461 | $3.31 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 17 | $2.26 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 78 | $1.99 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 16 | $0.46 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 169 | $0.22 |
| 99153 | Mod sedat endo service >5yrs | 0% | 17 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 416 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 345 | $0.00 |
| J3490 | Unclassified drugs | 0% | 3,142 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 15 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 92 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 14 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 113 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 140 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 36 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 172 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 51 | $0.00 |
| 82945 | 0% | 17 | $0.00 | |
| 84157 | 0% | 17 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 47 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 21 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 439 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 825 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 395 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 224 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 12 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 47 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 709 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 49 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,358 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 26 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 401 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 109 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 433 | $0.00 |
| C1729 | Catheter, drainage | 0% | 34 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 149 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMANNIX, MARY (FACHE)
| Provider | Location | Paid |
|---|---|---|
| Augusta Medical Group | Fishersville, VA | $12.60M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.